Skip to content
NeuroTechGuide

Ruiyi Xulian raises nearly RMB 100 million for an implanted brain-spine interface

The Suzhou start-up's Pre-A+ round will fund clinical work on its implanted bidirectional interface for spinal cord injury and stroke, currently in investigator-initiated trials.

In briefFundingImplantsClinical trials

Suzhou-based Ruiyi Xulian (瑞意旭联) has closed a Pre-A+ round of nearly RMB 100 million (about $14 million), Chinese venture outlet Pedaily reported on November 19. Puhua Capital and Furong Investment (复容投资) co-led, with Green Pine Capital Partners and Beigong Investment following on. The company, founded by Huang He, is building a modular, implanted “read and write” interface whose lead product is a brain-spine interface meant to restore movement after spinal cord injury or stroke. It makes its own flexible electrodes, stimulation and recording chips, and ceramic and sapphire packaging. Both indications are in investigator-initiated trials, and the funds will support registration trials as well as exploratory work on speech decoding, vision and depression.

The report gave no participant numbers or published results, so the investors’ description of “breakthrough” clinical data cannot be checked yet. Brain-spine interfaces of this kind have shown early promise in small European studies.

Learn more: Spinal cord stimulation · Closed-loop system

Share:XLinkedInBlueskyEmail

More news